Preview

Современная ревматология

Расширенный поиск

Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I

https://doi.org/10.14412/1996-7012-2020-4-7-15

Полный текст:

Аннотация

Представлены основные положения обновленных рекомендаций EULAR/ ERA–EDTA 2019 г. по терапии волчаночного нефрита. Обсуждается технология подготовки рекомендаций международной группой ревматологов, нефрологов, морфологов и педиатров. В основной части содержатся рекомендации по применению индукционной и поддерживающей терапии с использованием иммуносупрессоров, глюкокортикоидов и генно-инженерных биологических препаратов.
Рассмотрены вопросы ведения пациенток с беременностью и терминальной почечной недостаточностью.

Об авторах

Н. Л. Козловская
ФГАОУ ВО «Российский университет дружбы народов»; ГБУЗ г. Москвы «Городская клиническая больница им. А.К. Ерамишанцева Департамента здравоохранения города Москвы»
Россия

Россия, 117198, Москва, ул. Миклухо-Маклая, 6;
Россия, 129327, Москва, ул. Ленская, 15



С. К. Соловьев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия, 115522, Москва, Каширское шоссе, 34А;


Е. А. Асеева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Россия, 115522, Москва, Каширское шоссе, 34А;



Т. В. Попкова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия, 115522, Москва, Каширское шоссе, 34А;


Т. А. Панафидина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия, 115522, Москва, Каширское шоссе, 34А;


Е. Л. Насонов
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский университет)
Россия

кафедра ревматологии Института профессионального образования

Россия, 115522, Москва, Каширское шоссе, 34А;
Россия, 119991, Москва, ул. Трубецкая, 8, стр.2;



А. М. Лила
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России
Россия

кафедра ревматологии

Россия, 115522, Москва, Каширское шоссе, 34А;
Россия, 125993, Москва, ул. Баррикадная, 2/1, стр. 1



А. А. Меснянкина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия, 115522, Москва, Каширское шоссе, 34А;


Н. Ю. Никишина
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Россия, 115522, Москва, Каширское шоссе, 34А;


Литература

1. Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006 Aug;54(8):2550-7. doi: 10.1002/art.21955.

2. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003 Sep;82(5):299-308. doi: 10.1097/01.md.0000091181.93122.55.

3. Seligman VA, Lum RF, Olson JL, et al. Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med. 2002 Jun 15;112(9):726-9. doi: 10.1016/s0002-9343(02)01118-x.

4. Wilhelmus S, Bajema IM, Bertsias GK, et al. Lupus nephritis management guidelines compared. Nephrol Dial Transplant. 2016 Jun; 31(6):904-13. doi: 10.1093/ndt/gfv102. Epub 2015 Apr 28.

5. Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.

6. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835. doi: 10.2215/CJN.05780616. Epub 2016 Nov 7.

7. Parikh SV, Rovin BH. Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol. 2016 Oct;27(10):2929-39. doi: 10.1681/ASN.2016040415. Epub 2016 Jun 9.

8. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive Treatment for Proliferative Lupus Nephritis. Cochrane Database Syst Rev. 2018 Jun 29;6(6): CD002922. doi: 10.1002/14651858.CD002922.pub4.

9. Zickert A, Sundelin B, Svenungsson E, Gunnarsson I. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014 Aug 6;1(1):e000018. doi: 10.1136/lupus2014-000018. eCollection 2014.

10. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European renal AssociationEuropean dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012 Nov;71(11): 1771-82. doi: 10.1136/annrheumdis-2012-201940. Epub 2012 Jul 31.

11. Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-23. doi: 10.1136/annrheumdis2020-216924. Epub 2020 Mar 27.

12. Van der Heijde D, Aletaha D, Carmona L, et al. 2014 update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015 Jan; 74(1):8-13. doi: 10.1136/annrheumdis-2014-206350. Epub 2014 Sep 26.

13. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing Guideline development, reporting and evaluation in health care. CMAJ. 2010 Dec 14;182(18):E839-42. doi: 10.1503/cmaj.090449. Epub 2010 Jul 5.

14. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004 Feb;65(2):521-30. doi: 10.1111/j.1523-1755.2004.00443.x.

15. Erre GL, Bosincu L, Faedda R, et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int. 2014 Apr;34(4):535-41. doi: 10.1007/s00296-013-2900-3.

16. Rijnink EC, Teng YKO, Wilhelmus S, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017 May 8; 12(5):734-43. doi: 10.2215/CJN.10601016. Epub 2017 May 4.

17. Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheumatol. 2015 May;67(5):1305-13. doi: 10.1002/art.39026.

18. Tamirou F, D'Cruz D, Sangle S, et al. Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2016 Mar; 75(3):526-31. doi: 10.1136/annrheumdis2014-206897. Epub 2015 Mar 10.

19. Tamirou F, Lauwerys BR, Dall'Era M, et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the maintain nephritis trial. Lupus Sci Med. 2015 Nov 12;2(1):e000123. doi: 10.1136/lupus-2015-000123. eCollection 2015.

20. Mackay M, Dall'Era M, Fishbein J, et al. Establishing surrogate kidney end points for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheumatol. 2019 Mar;71(3):411-19. doi: 10.1002/art.40724. Epub 2019 Feb 1.

21. Ugolini-Lopes MR, Seguro LPC, Castro MXF, et al. Early proteinuria response: a valid real-life situation predictor of long-term lupus renal outcome in an ethnically diverse group with severe biopsyproven nephritis? Lupus Sci Med. 2017 Jun 12;4(1):e000213. doi: 10.1136/lupus-2017-000213. eCollection 2017.

22. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001 Aug 21;135(4):248-57. doi: 10.7326/0003-4819-135-4-200108210-00009.

23. Dall'Era M, Stone D, Levesque V, et al. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011; 63:351-7. 2011 Mar;63(3). doi: 10.1002/acr.20397. Epub 2010 Nov 15.7.

24. Dall'Era M, Levesque V, Solomons N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015 May 20;2(1): e000089. doi: 10.1136/lupus-2015-000089. eCollection 2015.

25. Touma Z, Urowitz MB, IbaЦez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014 Apr;41(4):688-97. doi: 10.3899/jrheum.130005. Epub 2014 Jan 15.

26. Tunnicliffe DJ, Palmer SC, Henderson L, et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018 Jun 29;6(6):CD002922. doi: 10.1002/14651858.CD002922.pub4.

27. ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol. 2014 Nov; 66(11):3096-104. doi: 10.1002/art.38790.

28. Mehra S, Usdadiya JB, Jain VK, et al. Comparing the efficacy of low-dose vs highdose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int. 2018 Apr;38(4):557-68. doi: 10.1007/s00296-018-3995-3. Epub 2018 Feb 15.

29. Boumpas DT, Austin HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992 Sep 26;340(8822):741-5. doi: 10.1016/0140-6736(92)92292-n.

30. Rovin BH, Solomons N, Pendergraft WF, et al. A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis. Kidney Int. 2019 Jan;95(1): 219-31. doi: 10.1016/j.kint.2018.08.025. Epub 2018 Nov 9.

31. Wang S, Li X, Qu L, et al. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study. Lupus. 2012 Aug;21(9):1025-35. doi: 10.1177/0961203312448105. Epub 2012 May 8.

32. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2018 Jul; 72(1):157. doi: 10.1053/j.ajkd.2018.05.001. Epub 2018 May 16.

33. Choi CB, Won S, Bae SC. Outcomes of multitarget therapy using mycophenolate mofetil and tacrolimus for refractory or relapsing lupus nephritis. Lupus. 2018 May; 27(6):1007-11. doi: 10.1177/0961203318758505. Epub 2018 Feb 15.

34. Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: a systematic review and meta-analysis. Autoimmun Rev. 2016 Jan;15(1):93-101. doi: 10.1016/j.autrev.2015.09.006. Epub 2015 Sep 30.

35. Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015 Jan 6;162(1):18-26. doi: 10.7326/M14-1030.

36. Palmer SC, Tunnicliffe DJ, Singh-Grewal D, et al. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis. 2017 Sep;70(3):324-36. doi: 10.1053/j.ajkd.2016.12.008. Epub 2017 Feb 21.

37. Yap DYH, Yu X, Chen XM, et al. Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. Nephrology (Carlton). 2012 May; 17(4):352-7. doi: 10.1111/j.1440-1797.2012.01574.x.

38. Pokroy-Shapira E, Gelernter I, Molad Y. Evolution of chronic kidney disease in patients with systemic lupus erythematosus over a long-period follow-up: a single-center inception cohort study. Clin Rheumatol. 2014 May;33(5):649-57. doi: 10.1007/s10067-014-2527-0. Epub 2014 Feb 19.

39. Cunha C, Alexander S, Ashby D, et al. Hydroxycloroquine blood concentration in lupus nephritis: a determinant of disease outcome? Nephrol Dial Transplant. 2018 Sep 1; 33(9):1604-10. doi: 10.1093/ndt/gfx318.

40. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006 Jun;21(6): 1541-8. doi: 10.1093/ndt/gfk073. Epub 2006 Feb 2.

41. Mok CC, Tse SM, Chan KL, et al. Effect of immunosuppressive therapies on survival of systemic lupus erythematosus: a propensity score analysis of a longitudinal cohort. Lupus. 2018 Apr;27(5):722-7. doi: 10.1177/0961203317739129. Epub 2017 Oct 31.

42. Pakchotanon R, Gladman DD, Su J, et al. Sustained complete renal remission is a predictor of reduced mortality, chronic kidney disease and end-stage renal disease in lupus nephritis. Lupus. 2018 Mar;27(3): 468-74. doi: 10.1177/0961203317726376. Epub 2017 Aug 31.

43. Marmor MF, Kellner U, Lai TYY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016 Jun; 123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058. Epub 2016 Mar 16.

44. Arends S, Grootscholten C, Derksen RH, et al. Long-term follow-up of a randomised controlled trial of azathioprine/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis. Ann Rheum Dis. 2012 Jun;71(6):966-73. doi: 10.1136/annrheumdis-2011-200384. Epub 2011 Nov 29.

45. Yap DYH, Tang C, Ma MKM, et al. Longterm data on disease flares in patients with proliferative lupus nephritis in recent years. J Rheumatol. 2017 Sep;44(9):1375-83. doi: 10.3899/jrheum.170226. Epub 2017 Jul 1.

46. Moroni G, Quaglini S, Gravellone L, et al. Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients. Semin Arthritis Rheum. 2012 Apr;41(5):642-51. doi: 10.1016/j.semarthrit.2011.08.002. Epub 2012 Jan 28.

47. Fernandes das Neves M, Irlapati RVP, Isenberg D. Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years. Rheumatology (Oxford). 2015 Aug;54(8):1403-7. doi: 10.1093/rheumatology/kev003. Epub 2015 Feb 27.

48. Moroni G, Longhi S, Giglio E, et al. What happens after complete withdrawal of therapy in patients with lupus nephritis. Clin Exp Rheumatol. Jul-Aug 2013;31(4 Suppl 78): S75-81. Epub 2013 Oct 4.

49. Moroni G, Gatto M, Raffiotta F, et al. Can we withdraw immunosuppressants in patients with lupus nephritis in remission? An expert debate. Autoimmun Rev. 2018 Jan;17(1): 11-8. doi: 10.1016/j.autrev.2017.11.003. Epub 2017 Nov 3.

50. Rivera F, Mеrida E, Illescas ML, et al. Mycophenolate in refractory and relapsing lupus nephritis. Am J Nephrol. 2014;40(2): 105-12. doi: 10.1159/000365256. Epub 2014 Jul 30.

51. Kasitanon N, Boripatkosol P, Louthrenoo W. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria. Int J Rheum Dis. 2018 Jan; 21(1):200-7. doi: 10.1111/1756-185X.13152. Epub 2017 Sep 13.

52. Mok CC, To CH, Yu KL, et al. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study. Lupus. 2013 Oct;22(11):1135-41. doi: 10.1177/0961203313502864. Epub 2013 Aug 30.

53. Sheikholeslami M, Hajialilo M, Rasi Hashemi SS, et al. Low dose cyclosporine A in the treatment of resistant proliferative lupus nephritis. Mod Rheumatol. 2018 May;28(3):523-29. doi: 10.1080/14397595.2017.1352479. Epub 2017 Jul 28.

54. Fei Y, Wu Q, Zhang W, et al. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study. Clin Exp Rheumatol. Jan-Feb 2013;31(1):62-8. Epub 2012 Aug 30.

55. Alshaiki F, Obaid E, Almuallim A, et al. Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol. 2018 Jul;5(2):118-26. doi: 10.5152/eurjrheum.2018.17096. Epub 2018 Feb 13.

56. Weidenbusch M, Römmele C, Schröttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 Jan;28(1):106-11. doi: 10.1093/ndt/gfs285. Epub 2012 Jul 3.

57. Davies RJ, Sangle SR, Jordan NP, et al. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis. Lupus. 2013 May; 22(6):574-82. doi: 10.1177/0961203313483376. Epub 2013 Apr 30.

58. Jonsdottir T, Zickert A, Sundelin B, et al. Long-term follow-up in lupus nephritis patients treated with rituximab – clinical and histopathological response. Rheumatology (Oxford). 2013 May;52(5):847-55. doi: 10.1093/rheumatology/kes348. Epub 2013 Jan 3.

59. Zhang J, Zhao Z, Hu X. Effect of rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015 May;72(1):197-201. doi: 10.1007/s12013-014-0437-z.

60. Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1502-9. doi: 10.2215/CJN.01070118. Epub 2018 Aug 8.

61. McCarthy EM, Sutton E, Nesbit S, et al. Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles lupus assessment group biologics register. Rheumatology (Oxford). 2018 Mar 1;57(3): 470-79. doi: 10.1093/rheumatology/kex395.

62. Fernandez-Nebro A, de la Fuente JLM, Carreno L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012 Sep;21(10):1063-76. doi: 10.1177/0961203312446627. Epub 2012 Jul 11.

63. Dooley MA, Houssiau F, Aranow C, et al. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus. 2013 Jan;22(1):63-72. doi: 10.1177/0961203312465781.

64. Stohl W, Schwarting A, Okada M, et al. Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a Fifty-Two-Week randomized, doubleblind, placebo-controlled study. Arthritis Rheumatol. 2017 May;69(5):1016-27. doi: 10.1002/art.40049. Epub 2017 Apr 7.

65. Iaccarino L, Bettio S, Reggia R, et al. Effects of belimumab on flare rate and expected damage progression in patients with active systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017 Jan;69(1):115-23. doi: 10.1002/acr.22971. Epub 2016 Nov 18.

66. Sciascia S, Radin M, Yazdany J, et al. Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev. 2017 Mar;16(3):287-293. doi: 10.1016/j.autrev.2017.01.010. Epub 2017 Jan 29.

67. Parodis I, Sjöwall C, Jönsen A, et al. Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus. Autoimmun Rev. 2017 Apr; 16(4):343-51. doi: 10.1016/j.autrev.2017.02.005. Epub 2017 Feb 13.

68. GSK. https://www.gsk.com/en-gb/media/press-releasesgsk-announcespositive-headline-results-in-phase-3-studyof-benlysta-in-patients-with-lupus- nephritis/

69. Kraaij T, Kamerling SWA, de Rooij ENM, et al. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun. 2018 Jul; 91:45-54. doi: 10.1016/j.jaut.2018.03.003. Epub 2018 Apr 7.

70. Sakthiswary R, D’Cruz D. Intravenous immunoglobulin in the therapeutic armamentarium of systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore). 2014 Oct;93(16):e86. doi: 10.1097/MD.0000000000000086.


Для цитирования:


Козловская Н.Л., Соловьев С.К., Асеева Е.А., Попкова Т.В., Панафидина Т.А., Насонов Е.Л., Лила А.М., Меснянкина А.А., Никишина Н.Ю. Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов. Часть I. Современная ревматология. 2020;14(4):7-15. https://doi.org/10.14412/1996-7012-2020-4-7-15

For citation:


Kozlovskaya N.L., Solovyev S.K., Aseeva E.A., Popkova T.V., Panafidina T.A., Nasonov E.L., Lila A.M., Mesnyankina A.A., Nikishina N.Yu. The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I. Modern Rheumatology Journal. 2020;14(4):7-15. (In Russ.) https://doi.org/10.14412/1996-7012-2020-4-7-15

Просмотров: 412


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)